Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CCAP and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CCAP and 80,000+ other tickers.
See exactly how CCAP's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CCAP and 80,000+ other tickers.
Crescent Capital BDC, Inc. functions as a Business Development Company (BDC), managing a fund dedicated to private equity, leveraged buyouts, and providing loan capital. The firm's strategy centers on making direct investments, with a specific focus on the middle market segment. Its investment mandate is exclusively for opportunities within the United States.
Crescent Capital BDC, Inc. faces ongoing headwinds, with a 19% dividend cut following rising non-accruals and declining investment income. Despite a steep 39% discount to NAV and a 12%+ yield, I remain cautious given persistent inflation and the potential for further downside. CCAP's Q1 saw net investment income drop to $0.38/share and non-accruals spike to 5.7% at cost, pressuring NAV and dividend sustainability.
Crescent Capital BDC, Inc. trades at a 39% NAV discount after a 19% dividend cut was announced due to falling NII. CCAP's non-accrual ratio doubled year-over-year to 3.6%, based on fair value, pressuring net investment income and dividend coverage. The portfolio is 92% first liens, and the forward dividend yield is 12%, with Q1'26 coverage at 1.0x.
Crescent Capital BDC, Inc. continues to underperform the index. Part of it is justified; part of it isn't. As of today, CCAP trades 40% below NAV and offers a yield of almost 13% that is underpinned by strong earnings coverage.
ACRE, CWST and CCAP have been added to the Zacks Rank #5 (Strong Sell) List on June 16, 2026.
CCAP, DAVA and RH have been added to the Zacks Rank #5 (Strong Sell) List on June 12, 2026.